Trial Profile
A Randomized Phase II Pilot Study to Evaluate Safety and Efficacy of the Addition of Vismodegib to Standard Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary) ; Cyclophosphamide; Epirubicin; Granulocyte-macrophage colony-stimulating factors; Paclitaxel
- Indications Breast cancer
- Focus Adverse reactions
- Acronyms SHH-CM
- 28 Jul 2015 New trial record